UGP2 (UDP-glucose pyrophosphorylase 2) catalyzes the conversion of glucose-1-phosphate to UDP-glucose, a critical precursor for glycogen synthesis and protein glycosylation 1. Beyond its canonical metabolic role, UGP2 functions as a TP53 target gene that protects endothelial cells from apoptosis by regulating reactive oxygen species homeostasis 2, supporting vascular homeostasis and potentially preventing atherosclerosis progression 2. In disease contexts, UGP2 exhibits paradoxical roles. In peripheral artery disease, UGP2 induction promotes angiogenesis and perfusion recovery through enhanced protein glycosylation 1. Conversely, UGP2 is consistently upregulated in multiple malignancies—including glioblastoma 3, gallbladder cancer 4, breast cancer (particularly triple-negative subtype) 5, pancreatic cancer 6, and lung cancer 7—where elevated expression correlates with aggressive tumor behavior, poor differentiation, metastasis, and reduced survival 34567. Notably, in hepatocellular carcinoma, LOW UGP2 expression associates with tumor progression and poor prognosis 8, suggesting tissue-specific functional differences. The GLUT1-UAP1-UGP2 metabolic axis promotes N-linked glycosylation-dependent cancer aggressiveness 7. UGP2 represents both a prognostic biomarker and potential therapeutic target across multiple disease contexts.